



BETA DRUGS LIMITED

BDL/PKL/SEC/2025-26

12th February, 2026

**To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East), Mumbai – 400051**

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Revision in Valuation Report of Beta Drugs Limited in relation to Preferential Issue for acquisition of Nivian Life Sciences Private Limited

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that there has been a revision in the Valuation Report of Beta Drugs Limited issued by Mr. Hitesh Jhamb, Registered Valuer, in connection with the proposed preferential issue by Beta Drugs Limited for the acquisition of Nivian Life Sciences Private Limited.

Earlier, the valuation under the Income Approach and the Cost Approach was undertaken based on standalone financial statements of Beta Drugs Limited. However, upon further review and for the purpose of presenting a more comprehensive financial position, the valuation has now been carried out based on the consolidated financial statements.

The revised Valuation Report dated 08.01.2026 is available on the website of the Company at the following link:

<https://www.betadrugslimited.com/wp-content/uploads/2026/02/VALUATION-REPORT-08.01.2026.pdf>

This is for your information and record.

**Thanking You
Your's faithfully
For Beta Drugs Ltd.**

Beta Drugs Limited

Company Secretary
ACS - 24684

**Rajni Brar
Company Secretary**

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com